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Abstract
Yes-associated protein (YAP) is a main mediator of the Hippo pathway and pro-
motes cancer development and progression in human lung cancer. We sought to
determine whether inhibition of YAP suppresses metastasis of human lung adeno-
carcinoma in a murine model. We found that metastatic NSCLC cell lines H2030-
BrM3(K-rasG12C mutation) and PC9-BrM3 (EGFRDexon19 mutation) had a significantly
decreased p-YAP(S127)/YAP ratio compared to parental H2030 (K-rasG12C muta-
tion) and PC9 (EGFRDexon19 mutation) cells (P < .05). H2030-BrM3 cells had signifi-
cantly increased YAP mRNA and expression of Hippo downstream genes CTGF and
CYR61 compared to parental H2030 cells (P < .05). Inhibition of YAP by short hair-
pin RNA (shRNA) and small interfering RNA (siRNA) significantly decreased mRNA
expression in downstream genes CTGF and CYR61 in H2030-BrM3 cells (P < .05).
In addition, inhibiting YAP by YAP shRNA significantly decreased migration and
invasion abilities of H2030-BrM3 cells (P < .05). We are first to show that mice
inoculated with YAP shRNA-transfected H2030-BrM3 cells had significantly
decreased metastatic tumour burden and survived longer than control mice
(P < .05). Collectively, our results suggest that YAP plays an important role in pro-
moting lung adenocarcinoma brain metastasis and that direct inhibition of YAP by
shRNA suppresses H2030-BrM3 cell brain metastasis in a murine model.
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1 | INTRODUCTION
Lung adenocarcinoma accounts for approximately 40% of primary
lung cancer worldwide, and in most patients, the disease is
already metastatic at the time of their initial diagnosis.1,2 Metasta-
sis in lung adenocarcinoma is a major morbidity that is associated
with poor prognosis and an overall 5-year survival rate less than
7%.3-6 Despite the developments of drugs targeting specific can-
cer-driven mutations, treatment options for metastatic lung adeno-
carcinoma without targetable mutations remain quite limited. For
example, the epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitor (TKI) erlotinib is an effective target therapy for
metastatic lung adenocarcinoma harbouring EGFR mutations such
as exon 19 deletion or exon 21 L858R mutations. Erlotinib had a
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better response rate and fewer side effects than conventional
chemotherapy in treating patients with EGFR mutant metastatic
lung adenocarcinoma.7-10 K-ras mutation is frequent in patients
with lung adenocarcinoma (15%-30%), but there is still no
approved effective target therapy for K-ras mutant metastatic lung
adenocarcinoma.10-12
Yes-associated protein (YAP), a key mediator protein in the
Hippo (also known as the Salvador-Warts-Hippo) signalling path-
way, has been reported to promote development of various can-
cers.13-15 YAP has been suggested as a potential therapeutic target
for melanoma, mesothelioma and hepatocellular carcinoma.16-18
YAP was also identified in human non-small-cell lung cancer
(NSCLC) and is correlated with drug resistance and tumorigene-
sis.14,19-21 A previous study reported that because some NSCLC
cell lines harbouring K-ras mutations were not K-ras-dependent
cells, K-ras may be not an appropriate therapeutic target.22 Fur-
thermore, YAP appears to take over K-ras as a cancer driver in
NSCLC and pancreatic ductal adenocarcinoma, and YAP was identi-
fied as a central driver of compensation for K-ras-dependent
NSCLC when there is loss of K-ras signalling.23-25 Metastatic lung
adenocarcinoma cell line H2030-BrM3 (K-rasG12C mutation) was
derived from lung adenocarcinoma cell line H2030 (K-rasG12C muta-
tion), which has a known cancer-driven K-ras mutation and a high
potential of metastasis in murine models.26,27 Although an impor-
tant regulator, serpin I1 (neuroserpin), was identified in H2030-
BrM3 cells to promote brain metastasis, rare study found effective
treatments for metastatic K-ras mutant lung adenocarcinoma in
murine models.27
We sought to determine whether there is increased Hippo/YAP
signalling pathway reporter activity and YAP expression in metastatic
lung adenocarcinoma cells. In addition, we investigated whether
direct inhibition of YAP suppresses human lung adenocarcinoma
H2030-BrM3 cell metastasis in vivo.
2 | MATERIALS AND METHODS
2.1 | Cell culture
Human metastatic NSCLC cell lines H2030-BrM3 (K-rasG12C muta-
tion) (P9) and PC9-BrM3 (EGFRDexon19 mutation) (P40) were kindly
provided by Professor Joan Massague (Metastasis Research Center,
Memorial Sloan Kettering Cancer Center, New York, NY) and
authenticated by left ventricle inoculation as previously
described.26,27 Parental human NSCLC cell line PC9 (P10) was a gift
from Dr. Jasmine G. Lee (Department of Internal Medicine, Division
of Respiratory Medicine, University of California Davis, Davis) and
authenticated by erlotinib treatment in a viability assay.28 Human
NSCLC cell line H2030 was obtained from American Type Culture
Collections (ATCC) (Manassas, VA) and passaged for fewer than
6 months after receipt from ATCC. Cell lines were maintained in
RPMI-1640 supplemented with 10% heat-inactivated foetal bovine
serum and streptomycin (100 mg/mL), and were cultured at 37°C in
a humid incubator with 5% CO2.
2.2 | Animal studies
All in vivo experiments strictly followed the UCSF institutional guide-
lines (Institutional Animal Care and Use Committee approval number:
AN103205-03). Athymic nude (CrTac:NCr-Foxn1nu) female mice, 6-
8 weeks of age, were purchased from Taconic Farms, Inc (Hudson,
NY 12534). A metastatic murine model was created by injecting
500 000 H2030-BrM3, YAP shRNA-transfected H2030-BrM3 or
control shRNA-transfected H2030-BrM3 cells suspended with
100 lL of PBS into the left ventricle via a percutaneous approach as
previously described.26,27 The mice were killed when they showed
symptoms of paralysis or appeared extremely sick, according to the
guidelines established by the UCSF Laboratory Animal Resource
Center, and tumour tissues were collected.
Bioluminescent imaging (Caliper Life Sciences, Waltham, MA)
was used to monitor in vivo metastasis. D-luciferin potassium salt
(Syd Labs, Natick, MA) was injected intraperitoneally into the mice
at a dose of 150 mg/kg, and mice were anaesthetized by inhalant
isoflurane 1%-5% in oxygen. After 10 minutes, the mice were placed
into the Xenogen IVIS spectrum imaging system. Images were
recorded with an exposure time of 1 minute. Survival was measured
from the day of H2030-BrM3 cell injection to the day mice were
killed.
2.3 | Cell viability assay
Parental PC9 and PC9-BrM3 cells were cultured in a 96-well plate
and treated with different doses of erlotinib (Selleckchem; Houston,
TX) (0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100 lmol/L). H2030-BrM3
cells transfected with control, YAP short hairpin RNA (shRNA) and
YAP shRNA-2 were cultured in a 96-well plate. After 72 hours of
incubation, cells were lysed and CellTiter-Glo Luminescent Cell Via-
bility Assay reagent (Promega) was added to generate luminescent
signalling. Luminescent signalling was detected using the GloMax-96
Microplate Luminometer. GraphPad Prism 5.0 software (GraphPad
Software, Inc., La Jolla, CA) was used to analyse proportional cell via-
bility and calculate dose-response curves and IC50.
2.4 | Short hairpin RNA transfection and cell
selection
Yes-associated protein shRNA#1 and control shRNA lentiviral parti-
cles were purchased from Santa Cruz Biotechnology, Inc (Dallas, TX).
YAP shRNA#2 lentiviral particles were purchased from Sigma-Aldrich
(St. Louis, MO) and had a different targeting sequence from YAP
shRNA#1. H2030-BrM3 cells were placed into 12-well plates and
grown to 70% confluence. The particles were mixed with transfec-
tion medium and reagents according to the manufacturer’s protocol
and then added to the cells. Bulk selection by adding puromycin or
geneticin (Life Technologies Corporation) in culture medium was
started at day 3 after transfection. Puromycin at a concentration of
2.5 lg/mL and mixed with culture medium was used for YAP
shRNA#1- and control shRNA-transfected cell selection. Geneticin at
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a concentration of 500 lg/mL mixed with culture medium was used
for YAP shRNA#2-transfected cell selection. The duration from the
beginning of puromycin or geneticin selection to shRNA-transfected
cell ready for intracardiac injection was at least 2 months. The effi-
cacy of transfection was confirmed by Western blotting.
2.5 | Luciferase gene, small interfering RNA and
cDNA plasmid transfection
For luciferase gene transfection, the pGreenFire1-CMV Virus
(pTRH1 CMV dscGFP T2A Fluc) Positive Control was purchased
from System Bioscience LLC (Palo Alto, CA). Virus particles were
mixed with transfection reagents and medium according to the man-
ufacturer’s protocol and added to the H2030-BrM3, YAP shRNA-
transfected and control shRNA-transfected H2030-BrM3 cells
cultured in 12-well plates. The efficacy of transfection was deter-
mined by fluorescence microscopy.
EGFR small interfering RNA (siRNA) and K-ras siRNA were pur-
chased from Santa Cruz Biotechnology, Inc (Dallas, TX). The
SMARTPool siRNA that targets YAP was purchased from Dharma-
con (Pittsburgh, PA), and the targeting sequence was different from
YAP shRNA#1 and YAP shRNA#2. Cells were transfected with
100 nmol/L of siRNA using Lipofectamine RNAiMAX (Invitrogen,
Carlsbad, CA).
The YAP plasmid DNA used to overexpress the YAP gene in the
cells was purchased from Addgene (Cambridge, MA). Cells were
placed in 6-well plates and transfected with 4 lg of YAP plasmid
DNA using Lipofectamine 2000 transfection reagent.
2.6 | Western blot analysis
The total amount of protein for each sample was 20 lg, and the
samples were run on 4%-20% gradient SDS-polyacrylamide gels
(Bio-Rad Laboratories, Inc., Hercules, CA) and then were trans-
ferred to immobilon-P nitrocellulose membranes (Millipore, Beller-
ica, MA). The membranes were probed with rabbit anti-YAP (Cell
Signaling, 4912; 1:1000), rabbit anti-phospho-Yap Ser127 (Cell Sig-
nalling, 9411; 1:1000), mouse antineuroserpin(serpin I1) (Abcam,
ab125097; 1:500) and mouse anti-GAPDH (Sigma-Aldrich, 100242-
MM05; 1: 10 000) in 4°C overnight after being blocked with 5%
non-fat milk. The membranes were then incubated with species-
specific-conjugated secondary antibodies (GE Dharmacon) at room
temperature for 1 hour. An ECL blotting analysis system (Amer-
sham Pharmacia Biotech, Piscataway, NJ) was used for detecting
protein expression.
2.7 | Luciferase reporter assay
The control shRNA-transfected H2030-BrM3 and YAP shRNA-
transfected H2030-BrM3 cells were placed in 24-well plates and
transfected with 89 GTIIC-luciferase plasmid (Addgene, Cambridge,
MA) and Renilla luciferase pRL-TK plasmid (Promega, Madison, WI)
using transfection reagent Lipofectamine 2000 (Invitrogen, Carlsbad,
CA). After 48-hour transfection, cells were lysed and luciferase activ-
ity was assayed using Dual-Luciferase Reporter Assay system (Pro-
mega, Madison, WI). All luciferase activities were normalized to
Renilla activity.
2.8 | DNA, RNA isolation, cDNA synthesis and
quantitative real-time RT-PCR
The High Pure RNA Isolation Kit (Roche, Indianapolis, IN) was used
for total RNA extraction from cells, and the QIAamp DNA Mini Kit
(Qiagen, Valencia, CA) was used for DNA extraction from cells. The
iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) was used to
transcribe RNA to the cDNA, and the cDNA was used as the tem-
plate for real-time PCR. Real-time PCR detection was using Taq-
Man Technology on an Applied Biosystems 7000 Sequence
Detection System (Applied Biosystems). Primers and probe
sequences commercially available (Applied Biosystems, Foster City,
CA) were used to detect YAP, CYR61, CTGF, serpin I1 and endoge-
nous control gene b-glucuronidase (GUSB) gene expression. Relative
Quantification Software (Applied Biosystems) was used for mRNA
expression analysis. Quantitative PCR for YAP copy number was
assayed by TaqMan Copy Number Assays, and the result was
analysed using CopyCaller Software v2.0 (Thermo Fisher Scientific,
Waltham, MA).
2.9 | Wound-healing and transwell invasion assays
Parental H2030-BrM3, YAP shRNA#1-transfected, control shRNA-
transfected H2030-BrM3 cells were sub-cultured in 6-well plates to
the condition of confluence. The plates were scratched by a 200-lL
pipette tip, and the cells were grown continuously. Phase contrast
images were taken at the time of the scratch (0 hour) and after
18 hours. The distance of cell movement was measured by ImageJ
software.
The 6-well plate transwell system (Corning Incorporated, USA)
was used for the transwell invasion assay, and the transwell inserts
were coated with 300 lL Matrigel. YAP shRNA-transfected and
control shRNA-transfected H2030-BrM3 cells were trypsinized and
resuspended in serum-free medium, and the cells were seeded on
the upper chamber of the transwell. The lower chamber was
infused with 2 mL complete growth medium (10% FBS). The gel
and cells in the upper chamber of the transwell were wiped after
incubation at 37°C for 48 hours. The membrane was stained by
crystal violet for 10 minutes after methanol fixation. Phase contrast
images were taken with a Primo Vert microscope (Zeiss, Gottingen,
Germany), and the cells on the lower side of the membrane were
counted.
2.10 | YAP immunofluorescence stain
H2030, H2030-BrM3 and YAP shRNA#1-transfected H2030-BrM3
cells were sub-cultured in an 8-well chamber slide (Thermo Fisher Sci-
entific, Waltham, MA). The cells were fixed with 100% methanol the
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next day. Cells were blocked in 5% goat serum for 1 hour, rabbit anti-
YAP primary antibody (Cell Signaling, 14074; 1:100) was added, and
cells were incubated in 4°C overnight. Goat anti-rabbit IgG (H+L) for
secondary antibody with Alexa Fluor 488 (Thermo Fisher Scientific, A-
11008; 1:800) for primary antibody detection were added, and cells
were incubated at room temperature for 1 hour. The cells were then
washed with PBS 3 times, and nuclei were stained by 2 lg/mL DAPI in
PBS. A fluorescence microscope (Zeiss Axioskop 2 microscope; Carl
Zeiss, Inc., Germany) was used to view stained cells, and images were
taken under a 209 objective lens.
2.11 | Tissue samples, histologic analysis and
immunohistochemistry
After mice were killed, the tumour tissues from metastatic sites
including lung, bone and brain were harvested and immediately
fixed in 10% paraformaldehyde for 24 hours. The tissues were then
transferred into 70% ethanol for storage and embedded in paraffin.
Histological sections of the tissues were stained with haematoxylin
and eosin (H&E stain) for general morphology analysis. An experi-
enced pathologist did the morphological analysis in the stained tis-
sues to verify tumour metastasis. Rabbit anti-YAP antibody (Cell
Signaling, 4912; 1:500) used for immunohistochemistry (IHC) stain-
ing was from Cell Signaling Technology. The brain tissues sections
of control- and YAP shRNA-transfected H2030-BrM3 intracardiac-
injected mice were immunostained. The brain tissue slides under-
went routine deparaffinization and rehydration. Slides were then
immersed in boiled 10 mmol/L sodium citrate buffer (pH 6.0), for
10 minutes. After cooling down, sections were incubated in 3%
hydrogen peroxide for 10 minutes and then washed in PBS three
times for 5 minutes. Sections were incubated with 10% normal
horse serum in PBS for 30 minutes. After being washed in PBS
three times, the sections were incubated overnight at 4°C with rab-
bit anti-YAP antibody (Cell Signaling, 4912; 1:500). The next day,
the sections were incubated with biotin-labelled secondary antibod-
ies and streptavidin-peroxidase (1: 30) for 20 minutes each. Slides
were stained for 5 minutes with 0.05% 3,30-diaminobenzidine
tetrahydrochloride freshly prepared in 0.05 mol/L Tris-HCl buffer
(pH 7.6) containing 0.024% hydrogen peroxidase. The slides then
were counterstained with haematoxylin, dehydrated and mounted
in Diatex. All images were taken by a Zeiss Axioskop 2 microscope
(Carl Zeiss Inc., Germany).
2.12 | ChIP assay
Chromatin ImmunoPrecipitation (ChIP) Assay Kit (Millipore Corpora-
tion) was used for the ChIP assay. Polyclonal antibodies for YAP and
control rabbit antibody for IgG used for ChIP were purchased from
Cell Signaling Technology.
Primers used for RT-PCR to amplify the neuroserpin(serpin I1)
gene were 50-ATAGTGCCTCTACCTCGAAG-30 and 50-TACTTAGGC
TGGTCCCTTGG-30, resulting in a product size of 250 bp.
2.13 | Statistical analysis
Data are expressed as mean  standard deviation (SD) from three
independent experiments. All statistical analyses were performed
with GraphPad Prism (version 5.0; GraphPad Software, San Diego,
CA, USA). t Tests were used to compare the differences between
two groups, and one-way ANOVA followed by Tukey’s multiple
comparisons was used to compare differences among >2 groups. A
Kaplan-Meier survival curve was calculated to determine survival in
the animal experiments and patients in tissue microarray. All P values
were 2-sided and considered to be statistically significant if P was
less than .05 (*P < .05, **P < .01, ***P < .001).
3 | RESULTS
3.1 | P-YAP(S127)/YAP ratio is decreased in
metastatic NSCLC cell lines
To investigate whether metastatic NSCLC cell lines have increased
YAP stability, Western blotting of YAP and p-YAP(S127) was
assayed. Western blotting showed that p-YAP(S127)/YAP ratio was
decreased in the metastatic NSCLC cell lines H2030-BrM3 (K-
rasG12C mutation) and PC9-BrM3 (EGFRDexon19 mutation) compared
to parental H2030 and PC9 cell lines (P < .05) (Figure 1A,B).
When the cell viability of PC9-BrM3 and parental PC9 cells trea-
ted by erlotinib was assayed, we found that the IC50 of erlotinib
was 0.600 lmol/L for PC9-BrM3 cells and 0.222 lmol/L for parental
PC9 cells (Figure 1C). In PC9-BrM3 cells, YAP protein expression
decreased after dose-dependent erlotinib treatment (Figure 1D).
Western blotting showed that YAP protein expression did not
change in K-ras siRNA-transfected H2030-BrM3 cells and that YAP
protein expression was decreased in EGFR siRNA-transfected PC9-
BrM3 cells (Figure 1E).
The finding that p-YAP(S127)/YAP ratio decreased in metastatic
NSCLC cell lines indicates that YAP stability increased. In the EGFR
mutant cell line PC9-BrM3 (EGFRDexon19 mutation), erlotinib treat-
ment decreased YAP protein expression. In K-ras mutant H2030-
BrM3 cells (K-rasG12C mutation), K-ras knockdown by K-ras siRNA
did not decrease YAP protein expression.
3.2 | YAP activation originates at the transcription
level in the metastatic NSCLC cell line H2030-BrM3
Quantitative PCR analysis of DNA copy number showed that paren-
tal H2030 and H2030-BrM3 cells had two copies of YAP (Fig-
ure 2A). YAP mRNA expression and that of the downstream genes
CTGF and CYR61 significantly increased in H2030-BrM3 compared
to parental H2030 cells (P < .01) (Figure 2B,C). Finally, immunofluo-
rescence staining showed that H2030-BrM3 cells had increased YAP
staining compared to parental H2030 cells (Figure 2D). Collectively,
these findings indicate that YAP activation originates at the tran-
scription level in the H2030-BrM3 cell line.
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3.3 | Inhibition of YAP decreased expression of
downstream genes CTGF and CYR61 in H2030-BrM3
cells
After YAP knockdown by siRNA and shRNA in H2030-BrM3 cells,
we found decreases in YAP protein expression (Figures 3A and S3A),
GTIIC reporter activity (Figure S3C), YAP mRNA expression and the
transcription of Hippo pathway downstream genes CTGF and
CYR61 (P < .05) (Figures 3B,C and S3B), and immunofluorescence
staining of YAP staining (Figure 3D).
Real-time PCR showed a significant threefold increase in mRNA
expression of the metastatic regulator serpin I1 (neuroserpin) in
H2030-BrM3 cells compared to parental H2030 cells (Figure S1A).
Sequence analysis of serpin I1 revealed four putative YAP binding
sites between 7372 and 6009 nucleotides upstream of the tran-
scription start site (Figure S1B). ChIP assays performed in H2030-
BrM3 cells demonstrated that YAP binds to the serpin l1 (neuroserpin)
enhancer (Figure S1C). To investigate whether inhibition of YAP
decreased the expression of serpin I1, protein expression was assayed
by Western blotting. Real-time PCR showed that in H2030-BrM3
cells, inhibiting YAP by siRNA and shRNA decreased serpin I1 protein
expression and decreased serpin I1 mRNA gene expression (P < .05)
(Figure 3E,F).
Collectively, these results show that inhibition of YAP decreased
expression of Hippo pathway downstream genes. We further found
that YAP binds to the metastatic regulator serpin l1 promoter, and
inhibition of YAP decreased serpin l1 expression at the protein and
mRNA level.
3.4 | Inhibition of YAP by shRNA restrains
migration and invasion abilities in H2030-BrM3 cells
To investigate whether inhibition of YAP restrains migration and inva-
sion abilities in H2030-BrM3 cells, control shRNA-transfected and
YAP shRNA#1-transfected H2030-BrM3 cells were cultured to nearly
confluence, scratched with a 200-lL pipette tip, and after 18 hours,
wound closure was measured. The wound closure rate decreased sig-
nificantly in the transfected cells (Figure 4A,B). The transwell assay
showed that the number of the cells that invaded the lower side of the
membrane decreased significantly in the YAP shRNA#1-transfected
cells (P < .01) (Figure 4C,D). We then repeated the transwell
assay using YAP shRNA#2 (another shRNA targeting a different YAP
F IGURE 1 Metastatic non-small-cell
lung cancer cell lines have decreased p-
YAP(S127)/YAP ratio compared to their
parental cell lines. A, Western blot analysis
of YAP and p-YAP(S127) protein
expression in H2030-BrM3, parental
H2030, PC9-BrM3 and parental PC9 cells.
B, Quantitative analysis of p-YAP (S127)/
YAP protein expression ratio in H2030-
BrM3, parental H2030, PC9-BrM3 and
parental PC9-BrM3 cells. C, Cell viability
analysis in PC9 and PC9-BrM3 cells after
erlotinib treatment. D, YAP protein
decreased after 0.1 and 1.0 lmol/L
erlotinib treatments in PC9-BrM3 cells. E,
YAP protein expression in H2030-BrM3
cells after K-ras knockdown and in PC9-
BrM3 cells after EGFR knockdown (error
bars indicate standard deviations; *P < .05
and **P ≤ .01)
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sequence from YAP shRNA#1). YAP shRNA#2-transfected H2030-
BrM3 cells had decreased invasion ability compared to control
shRNA-transfected H2030-BrM3 cells (P < .01) (Figure 4E,F). The cell
viability of H2030-BrM3 was assayed after YAP shRNA transfection
(Figure S3D,E). Our results verified that YAP shRNA transfection
indeed decrease migration and invasion abilities in H2030-BrM3 and
not by the effects of cell death.
We next investigated whether increased YAP expression promotes
metastatic potential in parental H2030 cells. In H2030 cells trans-
fected with YAP plasmid, YAP protein and mRNA expression were
increased compared to H2030 cells transfected with pcDNA 3.1 (Fig-
ure S2A,B). YAP plasmid-transfected H2030 cells also had increased
migration and invasion abilities compared to pcDNA 3.1-transfected
H2030 cells in migration and transwell assays (Figure S2C-F).
3.5 | Inhibition of YAP by shRNA suppresses brain
metastatic ability of H2030-BrM3 cells in vivo
To investigate whether YAP inhibition suppresses the metastatic
ability of H2030-BrM3 cells, control shRNA-transfected and YAP
F IGURE 2 H2030-BrM3 cells have
increased YAP mRNA, expression of
downstream genes CTGF and CYR61, and
YAP immunofluorescence staining
compared to parental H2030 cells. A,
QPCR for YAP DNA copy number analysis
showed that parental H2030 and H2030-
BrM3 cells have two copies of YAP. B,
YAP mRNA expression level significantly
increased in H2030-BrM3 cells. C, mRNA
expression of the Hippo downstream
genes CTGF and CYR61 mRNA
expressions significantly increased in
H2030-BrM3 cells. D, Immunofluorescence
stain assay showed that H2030-BrM3 cells
had increased YAP staining compared to
parental H2030 cells (error bars indicate
standard deviations; **P ≤ .01; and
***P ≤ .001)
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F IGURE 3 Downstream gene and metastatic regulator expression changes in H2030-BrM3 cells after YAP knockdown. A, YAP knockdown
by siRNA and shRNA decreased YAP protein expression in H2030-BrM3 cells. B, C, YAP mRNA and mRNA expression of Hippo downstream
genes CTGF and CYR61 significantly decreased in YAP shRNA-transfected H2030-BrM3 cells. D, Immunofluorescence stain assay showed that
YAP staining decreased in YAP shRNA#1-transfected H2030-BrM3 cells. E, YAP knockdown by siRNA and shRNA decreased serpin I1 protein
expression in H2030-BrM3 cells. F, YAP knockdown by shRNA and siRNA significantly decreased serpin I1 mRNA expression in H2030-BrM3
cells (error bars indicate standard deviations; *P < .05 and ***P ≤ .001)
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shRNA#1-transfected H2030-BrM3 cells were injected into nude
mice. We then repeated the in vivo experiment using YAP shRNA#2.
We found that the metastatic ability of H2030-BrM3 cells in this
murine model decreased significantly after YAP knockdown by
shRNA, as shown in bioluminescence images (P < .001) (Figure 5A,
B). Mice inoculated with YAP shRNA-transfected H2030-BrM3 cells
F IGURE 4 Analysis of cell migration and invasion abilities of H2030-BrM3 cells after inhibiting YAP by YAP shRNA. A, Decrease in cell
migration ability in H2030-BrM3 cells after YAP knockdown by YAP shRNA#1. B, Quantitative analysis of migration assay result, indicating
YAP knockdown by YAP shRNA#1 decreased cell migration ability in H2030-BrM3 cells. C, Decrease in cell invasion ability in H2030-BrM3
cells after YAP knockdown by YAP shRNA#1. D, Quantitative analysis of transwell invasion assay result, indicating YAP knockdown by YAP
shRNA#1 decreased cell invasion ability in H2030-BrM3 cells. E, Decrease in cell invasion ability in H2030-BrM3 cells after YAP knockdown
by YAP shRNA#2. F, Quantitative analysis of transwell invasion assay result, indicating YAP knockdown by YAP shRNA#2 decreased cell
invasion ability in H2030-BrM3 cells (error bars indicate standard deviations; **P ≤ .01)
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survived significantly longer than mice inoculated with control
shRNA-transfected H2030-BrM3 cells (P < .01) (Figure 5C).
3.6 | Inhibition of YAP by shRNA decreased
nucleus YAP immunohistochemistry stain of mouse
brain tumour tissues
Brain tissues were collected from control and YAP shRNA groups for
histological analysis after mice were killed. Haematoxylin and eosin
(H&E) stain showed tumour metastasis within brain tissues (Fig-
ure 6A). YAP IHC staining was performed to see the late effect of
shRNA transfection. The results showed that YAP IHC staining
decreased in YAP shRNA brain tissues compared to control brain tis-
sues (Figure 6A). Our result shows that inhibition of YAP by shRNA
decreased nucleus YAP IHC stain of mouse brain metastatic tumour
tissues.
4 | DISCUSSION
Our study provides several lines of evidence that suggest the
Hippo/YAP signalling pathway is important in promoting metastasis
of lung adenocarcinoma. First, we found that H2030-BrM3 (K-
rasG12C mutation) and PC9-BrM3 (EGFRDexon19 mutation) cells have
decreased p-YAP(S127)/YAP protein expression ratio compared to
parental H2030 and PC9 cells. Second, H2030-BrM3 cells have
increased YAP mRNA, expression of downstream genes CTGF and
CYR61, and YAP immunofluorescence staining compared to parental
H2030 cells. Finally, direct inhibition of YAP by YAP shRNA
decreased the metastatic ability of H2030-BrM3 cells in a murine
model.
According to recent studies, YAP takes over K-ras as a cancer
driver in NSCLC.23-25 A previous study also identified that some
NSCLC cell lines harbouring K-ras mutations were not K-ras-depen-
dent cells, and that for those cell lines, K-ras may be not a therapeu-
tic target.22 Moreover, H2030 cells (K-rasG12C mutation) are not
responsive to therapies targeting K-ras, mitogen-activated protein
(MAP)-ERK kinase (MEK) and the extracellular signal-regulated kinase
(ERK) signalling pathway.29–32 In our study, inhibition of K-ras by
K-ras siRNA in H2030-BrM3 cells did not decrease YAP protein
expression, which suggests these cells may not be K-ras-dependent.
Therefore, we investigated YAP as a therapeutic target for metasta-
sis of H2030-BrM3 cells because they have increased YAP mRNA
and YAP protein expression.
Another metastatic lung adenocarcinoma cell line PC9-BrM3
(EGFRDexon19 mutation) was derived from PC9 cells (EGFRDexon19
mutation) with a known EGFR exon 19 deletion mutation.28,31,32
Currently, erlotinib is effective in treating metastatic lung adenocar-
cinoma harbouring EGFR exon 19 deletion mutation.9,33-36 Our
results showed that YAP protein expression decreased after erlotinib
treatment and inhibition of EGFR by EGFR siRNA in PC9-BrM3 cells.
We recently reported crosstalk between Hippo/YAP and EGFR/ex-
tracellular signal-regulated kinase signalling pathways in human
NSCLC cells.19,21 Collectively, PC9-BrM3 cells are dependent on the
EGFR signalling pathway and inhibiting that pathway can inhibit the
YAP signalling pathway and control metastasis of PC9-BrM3 cells.
Yes-associated protein transcription can be stimulated by
SIRT1,37 and SIRT1 is highly expressed in NSCLC brain metastasis
tissues.38 Together, these finding may partially explain the increase
in YAP mRNA expression level in H2030-BrM3 cells as shown in our
study. Much work is needed to verify the source of increased YAP
transcription in metastatic NSCLC.
The activation of YAP forms autocrine loops with the ERBB
pathway to promote cancer progression, migration and invasion in
various cancers.39-42 Moreover, Hippo downstream genes CTGF and
CYR61 have been reported to activate integrin-mitogen-activated
protein kinase (MAPK) and the AKT signalling pathway and promote
cancer progression and metastasis in cancer.43-46 MAPK and the
AKT pathways negatively regulate Hippo kinase and reduce p-YAP
(S127).47,48 The decreased p-YAP(S127)/YAP ratio indicates an
increase in YAP stability, and then more YAPs enter nucleus to acti-
vate downstream gene expression. These findings may explain our
finding that YAP mRNA level increased modestly (about 1.5-fold),
but the reduction in p-YAP was more prominent. The mechanism of
high metastatic potential in H2030-BrM3 cells is summarized in Fig-
ure 5E.
In our study, YAP protein expression decreased more than 70%
after YAP knockdown by shRNA and siRNA, but the decrease in
GTIIC reporter activity and CTGF mRNA expression was not as great
as the decrease in YAP protein in our in vitro experiments. Actually,
YAP does not account for all the GTIIC reporter activity and other
mediators exist.49 Like GTIIC reporter activity, CTGF mRNA expres-
sion did not decrease as markedly as YAP protein after shRNA and
siRNA transfection in H2030-BrM3 cells because YAP is one of sev-
eral factors that control CTGF expression; for example, TGF-b can
control CTGF expression.50,51
Serpin I1 (neuroserpin) is an important regulator in promoting
brain metastasis of lung adenocarcinoma H2030-BrM3 cells in mur-
ine models. Serpin I1 helps cancer cells to infiltrate brain by inhibit-
ing plasminogen activator (PA)-plasmin system.27 In our study,
sequence analysis of serpin I1 revealed a putative YAP binding site
more than 6 kb upstream of the transcription start site, and it is
known that YAP can bind distal enhancers through TEAD to control
transcription of downstream genes.52 Using a ChIP assay, we
showed that YAP binds to the serpin l1 enhancer in H2030-BrM3
cells, and inhibiting YAP by YAP shRNA and YAP siRNA decreased
serpin I1 protein and mRNA expression in H2030-BrM3 cells. These
results suggest that YAP signalling may be involved in regulating ser-
pin I1, and through inhibition of YAP can partly suppress serpin I1
expression and then decrease the potential of brain metastasis in
H2030-BrM3 cells. These results also explained that inhibition of
YAP by shRNA did not suppress proliferation ability of H2030-BrM3
cells markedly, but brain metastasis occurred late in the in vivo
experiment of shRNA group.
To our knowledge, our study is first to provide the key evidence
that direct inhibition of YAP by shRNA suppresses lung
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adenocarcinoma H2030-BrM3 cell metastasis in a murine model.
This is one the best metastasis models that are currently available
using human lung cancer cells. Most unresectable lung cancer
patients (e.g., stage IV lung cancer) are at stage of colonization, and
the treatment options for these patients are very limited (e.g., TKI
and immunotherapy). Targeting this stage can be beneficial to
patients with late-stage lung cancer, although we also wish to find a
better metastasis models (e.g., orthotopic models) that can help us
to validate whether YAP is indeed a driver for the entire metastasis
process (as suggested in in vitro transwell experiments).6,26,27,53
Our study shows that YAP plays a key role in promoting brain
metastasis in lung adenocarcinoma H2030-BrM3 cells and that inhi-
bition of YAP can suppress brain metastasis in vivo. These findings
may have implications for future potential therapeutic strategies for
F IGURE 5 Inhibition of YAP by shRNA suppressed metastatic ability of H2030-BrM3 cells in a murine model (control shRNA n = 10, YAP
shRNA#1 n = 5, YAP shRNA#2 n = 5). A, Bioluminescence images of mice inoculated with control shRNA-transfected H2030-BrM3 cells, YAP
shRNA#1-transfected and YAP shRNA#2-transfected H2030-BrM3 cells. B, Tumour metastasis burden in control mice and mice inoculated
with YAP shRNA-transfected H2030-BrM3 cells based on photon flux (photons per second) (***P ≤ .001). C, Kaplan-Meier survival curves for
control mice and mice inoculated with YAP shRNA-transfected H2030-BrM3 cells. D, Summary of the hypothetical model of our study. In
H2030-BrM3 cells, activation of YAP occurs at transcription mRNA level and increases YAP protein expression and mRNA expression of
downstream genes CTGF and CYR61. CTGF/CYR61 forms an autocrine loop to activate the MAPK signalling pathway in H2030-BrM3 cells.
The enhancement of the MAPK signalling pathway increases the invasion and migration abilities and metastatic potential of H2030-BrM3 cells
F IGURE 6 Histological analysis of mice
brain tissue. A, H&E stain of brain tissues
from control mice and mice inoculated
with YAP shRNA-transfected H2030-BrM3
cells. B, YAP IHC stain of brain tissues
from control mice and mice inoculated
with YAP shRNA-transfected H2030-BrM3
cells. The scale bar = 100 lm
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K-ras mutant metastatic lung adenocarcinoma. More studies to vali-
date YAP as a therapeutic target for K-ras mutant human metastatic
lung adenocarcinoma are warranted.
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